

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Approval for Registration of an Additional Indication for Drug of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

15 June 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* for identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval for Registration of an Additional Indication for Drug of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement, or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the drug registration application for the additional indication of Luvometinib Tablets (trade name: 复迈宁, project no.: FCN-159, the “**Drug**”) of Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the “**Company**”), has been approved by the National Medical Products Administration (the “**NMPA**”). The approved indication is for the treatment of pediatric patients 2 years of age and older with relapsed or refractory Langerhans cell histiocytosis (LCH) after systemic therapy.

II. Registration Information of the Drug

Generic Name: Luvometinib Tablets

Dosage Form: Oral Tablet

Strength: 4mg, 1mg

Registration Category: Chemical, Class 2.4

Marketing Authorization Holder: Shanghai Fosun Pharmaceutical Industrial Development, Co., Ltd. * (上海復星醫藥產業發展有限公司)

III. Research and Development of the Drug and Marketing Situation of Similar Drugs

The Drug is an innovative small molecule chemical drug self-developed by the Group (i.e., the Company and its subsidiaries/units, the same applies below), which is a MEK1/2 selective inhibitor.

As at the date of this announcement (i.e., 15 June 2026), the regulatory or clinical progress of the Drug is as follows:

1. In addition to the newly indication approved, two other indications of the Drug has already been approved for marketing in China¹, including the treatment of (1) adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms; (2) pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

2. The drug registration application for another indication of the Drug (for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection) have been accepted by the NMPA and included in the List of Priority Review, namely.

3. In addition, several indications of the Drug are in clinical trials in China, including (1) the Drug for the treatment of pediatric patients with low-grade glioma is at the stage of Phase III clinical trial; (2) the Drug for the treatment of extracranial arteriovenous malformations is at the stage of Phase II clinical trial; (3) the Drug in combination with Anlotinib for the treatment of patients with KRAS-mutant advanced non-small cell lung cancer (NSCLC) is at the stage of Phase II clinical trial.

As of May 2026, the Group had invested approximately RMB699 million (unaudited) in total in the research and development of the Drug at this stage.

According to the latest data from IQVIA MIDAS^{TM2}, the sales of MEK1/2 selective inhibitor worldwide amounted to approximately US\$2,359 million in 2025.

¹ excluding Hong Kong, Macau and Taiwan, the same hereinafter.

² Data provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world.

IV. Impact on Listed Companies and Risk Warning

The approval of this new additional indication will help address unmet medical needs in the relevant rare tumor therapeutic area, and further enhance the Drug's market competitiveness.

Due to the industry characteristics of pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

15 June 2026

** For identification purposes only*